LRATD2 and cancer: The results considering the three-gene signature (POU5F1P1, PRDM14, and FAM84B) analyzed in 10 different cancer studies consisting 4,641 samples were limited to more than a 20% alteration frequency and minimum of 100 samples in the dataset.